Over-expression of endoglin (CD105): A marker of breast carcinoma-induced neo-vascularization

Anticancer Research

Volumn 18, Issue 5 A, 1998, Pages 3621-3628

  Bodey, Bela ^a,e   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e NONE   (United States)

Author keywords

Antiangiogenic therapy; Breast carcinomas; Carcinogenesis; Cellular immunophenotype (CIP); Endoglin (CD105 EDG); Endothelial cell markers; Neoplasm related angiogenesis (NRA); Vascular endothelial growth factor permeability factor (VEGF PF)

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; DIAMINOBENZIDINE; ENDOGLIN; MONOCLONAL ANTIBODY; REAGENT; STREPTAVIDIN; TUMOR MARKER;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BRAIN CORTEX; BREAST CARCINOMA; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; SKIN; SPLEEN; THYMUS; TISSUE SECTION; TONSIL; VASCULAR ENDOTHELIUM;

ANTIGENS, CD; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0031731630     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (137)

1. Harris JR, Lippman ME, Veronesi U, Willett W: Medical Progress: Breast cancer. N Engl J Med 327: 319-328, 1992.
2. Bailey LR, Roodi N, Verrier CS, Yee CJ, Dupont WD, Parl FF: Breast cancer and CYPIA1, GSTMI, and GSTTI polymorphisms: Evidence of a lack of association in Caucasians and African Americans. Cancer Res 58: 65-70, 1998.
3. Couillard S, Gutman M, Labrie C, Belanger A, Candas B, Labrie F: Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 58: 60-64, 1998.
4. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics 1997. CA Cancer J Clin 47: 5-27, 1997.
5. Henderson JC: Risk factors for breast cancer development. Cancer (Phila.) 71: 2127-2140, 1990.
6. Venitt S: Mechanisms of carcinogenesis and individual susceptibility to cancer. Clin Chem 40: 1421-1425, 1994.
7. Gastl G, Hermann T, Steurer M, Zmija J, Gunsilius E, Unger C, Kraft A: Angiogenesis as a target for tumor treatment. Oncology 54: 177-184, 1997.
8. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Med 1: 27-31, 1995.
9. Cockerill GW, Gamble JR, Vadas MA: Angiogenesis: models and modulators. Int Rev Cytol 159: 113-160, 1995.
10. Risau W: Differentiation of endothelium. FASEB J 9: 926-933, 1995.
11. Risau W, Flamme I: Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995.
12. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
13. Bicknell R, Harris AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8: 60-65, 1996.
14. Folkman J: Addressing tumor blood vessels. Nature Biotechnol 15: 510, 1997.
15. Folkman J: Angiogenesis and angiogenesis inhibition: an overview. EXS 79: 1-8, 1997.
16. Pietsch T, Valter MM, Wolf HK, von Deimling A, Su Huang H-J, Cavenee WK, Wiestler OD: Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93: 109-117, 1997.
17. Price JT, Bonovich MT, Kohn EC: The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol 32: 175-253, 1997.
18. Salven P, Heikkila MD, Anttonen A, Kajanti M, Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Modern Pathol 10: 1128-1133, 1997.
19. Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
20. Keck PJ, Hauser SD, Krivi G, Saazo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246:1309-1312, 1989.
21. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
22. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993.
23. Meir EG van, Polverini PJ, Chazin VR, Su Huang H-J, de Tribolet N, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet 8: 171-176, 1994.
24. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579, 1994.
25. Czubayko F, Smith RV, Chung HC, Wellstein A: Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem 269: 28243-28248, 1994.
26. Risau W: What, if anything, is an angiogenic factor? Cancer Metast Rev 15: 149-151, 1996.
27. Czubayko F, Liadet-Coopman EDE, Aigner A, Tuveson AT, Berchem GJ, Wellstein A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 3: 1137-1140, 1997.
28. Rak J, Kerbel RS: bFGF and tumor angiogenesis - back in the limelight? Nature Med 3: 1083-1084, 1997.
29. Dameron KM, Volpert OV, Taisnky MA, Bouck N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584, 1994.
30. Bertin N, Clezardin P, Kubiak R, Frappart L: Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Res 57: 396-399, 1997.
31. Choudhuri R, Zhang H-T, Donnini S, Ziehe M, Bicknell R: An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 57: 1814-1819, 1997.
32. Koochekpour S, Jeffers M, Rulong S, Taylor G, Klineberg E, Hudson EA, Resau JH, Vande Woude GF: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57: 5391-5398, 1997.
33. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE: Upregulation of endoglin (CD 105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy. Anticancer Res (In print), 1998.
34. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. Cancer Res 57: 136-140, 1997.
35. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149-153, 1995.
36. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, Fukui M: Expression vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55: 1189-1193, 1995.
37. Berkman RA, Merrill MJ, Reinhold WC, Monacci WT, Saxena A, Clark WC, Robertson JT, Ali IU, Oldfield EH: Expression of the vascular permeability factor /vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91: 153-159, 1993.
38. Morii K, Tanaka R, Washiyama K, Kumanishi T, Kuwano R: Expression of vascular endothelial growth factor in capillary hemangioblastoma. Biochem Biophys Res Commun 194: 749-755, 1993.
39. Wizigmann-Voos S, Breier G, Risau W, Plate KH: Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 55: 1358-1364, 1995.
40. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S, Nose T: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56: 2185-2190, 1996.
41. Plate KH, Breier G, Weich HA, Mennel HD, Risau W: Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520-529, 1994.
42. Melnyk O, Shuman MA, Kim KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res 56: 921-924, 1996.
43. Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, Martiny-Baron G: Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-I. J Biol Chem 272: 10382-10388, 1997.
44. Bouck N: Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis. Cancer Treat Res 63: 3-59-371, 1992.
45. van den Hoff A: Stromal involvement in malignant growth. Adv Cancer Res 50: 159-196, 1988.
46. Risau W, Lemmon V: Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125: 441-450, 1988.
47. Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nature Biotechnol 15: 1271-1275, 1997.
48. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
49. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdzar AF, King SW, Letarte M, Vitetta ES, Thorpe PE: Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy. Clin Cancer Res 1: 1623-1634, 1995.
50. Kumar P, Wang JM, Bernabeu C: CD105 and angiogenesis. J Pathol 178: 363-366, 1996.
51. Fernandez-Ruiz E, St-Jacques S, Bellon T, Letarte M, Bernabeu C: Assignment of the human endoglin gene (END) to 9q34->qter. Cytogenet Cell Genet 64: 204-207, 1993.
52. Wang JM, Kumar S, van Agthoven A, Kumar P, Pye D, Hunter RD: Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int J Cancer 62: 791-796, 1995.
53. Yamada N, Kato M, Yamashita H, Nister M, Miyazono K, Heldin CH, Funa K: Enhanced expression of transforming growth factor-beta and its type-I and type-II receptors in human glioblastoma. Int J Cancer 62: 386-392, 1995.
54. Henriksen R, Gobi A, Wilander E, Oberg K, Miyazono K, Funa K: Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF- beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest 73: 213-220, 1995.
55. Szekanecz Z, Haines GK, Harlow LA, Shah MR, Fong TW, Fu R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta 1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 76: 187-194, 1995.
56. Zhang H, Shaw AR, Mak A, Letarte M: Endoglin is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. J Immunol 156: 564-573, 1996.
57. Griffioen AW, Damen CA, Blijham GH, Groenewegen G: Endoglin/CD105 may not be an optimal tumor endothelial treatment target. Breast Cancer Res Treat 39: 239-242, 1996.
58. Shovlin CL, Scott J: Inherited diseases of the vasculature. Annu Rev Physiol 58: 483-507, 1996.
59. Pichuantes S, Vera S, Bourdeau A, Pece N, Kumar S, Wayner EA, Letarte M: Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens 50: 265-276, 1997.
60. Gougos A, Letarte M: Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 265: 8361-8364, 1990.
61. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J: Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67: 785-795, 1991.
62. Altomonte M, Montagner R, Fonsatti E, Colizzi F, Cattarossi I, Brasoveanu LI, Nicotra MR, Cattelan A, Natali PG, Maio M: Expression and structural features of endoglin (CD105), a transforming growth factor beta) and beta3 binding protein, in human melanoma. Br J Cancer 74: 1586-1591, 1996.
63. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 267: 19027-19030, 1992.
64. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C: Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 22: 393-397, 1992.
65. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, de Waal RM: A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 100: 27-34, 1993.
66. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, De Waal RM: Characteristics and possible function of endoglin, a TGF-beta binding protein. Behring Inst Mitt 92: 15-22, 1993.
67. Lopez-Casillas F, Payne HM, Andres JL, Massague J: Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124: 557-568, 1994.
68. Derynck R, Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta 1333: F105-F150, 1997.
69. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P, Miyazono K: Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta. J Biol Chem 269: 1995-2001, 1994.
70. Lastres P, Martin-Perez J, Langa C, Bernabeu C: Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 301: 765-768, 1994.
71. Bcllon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M, Bemabeu C: Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 23: 2340-2345, 1993.
72. Lastres P, Letamendia A, Zhang H, Rius C, Almendro N, Raab U, Lopez LA, Langa C, Fabra A, Letarte M, Bernabeu C: Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 133: 1109-1121, 1996.
73. Farmilo AJ, Stead RH: Fixation in immunocytochemistry. In: Handbook Immunochemical Staining Methods. (Naish SJ, ed) DAKO Corporation, 1989, pp24-29.
74. Weidner N: Intratumoral microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19, 1995.
75. Martin L, Holcombe C, Green B, Leinster SJ, Winstanley J: Is a histological section representative of whole tumour vascularity in breast cancer? Brit J Cancer 76: 40-43, 1997.
76. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein expression in various childhood astrocytoma subtypes: Significance in tumorprogression. AnticancerRes 17: 1187-1194, 1997.
77. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells. Anticancer Res 16: 3439-3446, 1996.
78. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors. Anticancer Res 17: 189-196, 1997.
79. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Nm23/nucleoside diphosphate (NDP) kinase expression in human malignant melanomas. Significance and implications in tumor biology. Anticancer Res 17: 505-512, 1997.
80. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493-498, 1997.
81. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance. Anticancer Res 17: 1311-1318, 1997.
82. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319-1330, 1997.
83. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
84. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
85. Battifora H, Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
86. Greene HSN: The transplantation of human brain tumors to the brain of laboratory animals. Cancer Res 13: 422-426, 1953.
87. Bennett HS, Luft JH, Hampton JL: Morphological classification of vertebrate blood capillaries. AmerJ Physiol 196: 381-390, 1959.
88. Dobbing J: The blood-brain barrier. Physiol Rev 41: 130-188, 1961.
89. Donahue S, Pappas G: Fine structure of capillaries of cerebral cortex of rat at stages of development. Amer J Anat 108: 331-349, 1961.
90. Tschirgi R: Blood-brain barrier: Fact or fantasy? Fed Proc 21: 665-676, 1962.
91. Shimoda A: An electron microscopic study of the developing rat brain concerned with the morphological basis of the blood-brain barrier. Acta Path Jap 13: 95-105, 1963.
92. Fox JL: Developments of recent thoughts on intracranial pressure and the blood-brain barrier. J Neurosurg 21: 909-967, 1964.
93. Krigman MR, Manuelidis EE: Morphological and permeability changes in the cerebral parenchyma adjacent to heterologous intracerebral tumors. J Neuropath Exp Neurol 22: 368-373, 1965.
94. Manuelidis EE, Dolin R: Fine structural studies on the vascularization of heterologously transplanted tumors. Ann NY Acad Sci 159: 432-445, 1969.
95. Roberts WG, Palade GE: Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 57: 765-772, 1997.
96. Clark WC, Bressler J: Transforming growth factor-β-like activity in tumors of the central nervous system. J Neurosurg 68: 920-924, 1988.
97. Zagzag D, Brem S, Robert F: Neovascularization and tumor growth in the rabbit brain: a model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol 131: 361-372, 1988.
98. Zagzag D, Miller DC, Sato Y, Rifkin DB, Burstein DE: Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50: 7393-7398, 1990.
99. Mapstone TB: Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. J Neurosurg 75: 447-451, 1991.
100. Brem S, Tsanaclis AMC, Gately S, Gross JL, Herblin WF: Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70: 2673-2680, 1992.
101. Takashashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H, Hatanaka M: Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798, 1992.
102. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362: 841-844, 1993.
103. Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD: Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and spread. Histopathology 28: 521-528, 1996.
104. St-Jacques S, Cymerman U, Pece N, Letarte M: Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 134: 2645-2657, 1994.
105. St-Jacques S, Forte M, Lye SJ, Letarte M: Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 57: 405-413, 1994.
106. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early- stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
107. Toi M, Yamamoto Y, Taniguchi T, Saji S, Hayashi K, Tominaga T: Regulation of endothelial growth factor expressions in breast cancer. Gan To Kagaku Ryoho 23(Suppl 1): 75-79, 1996.
108. Yoshiji H, Harris SR, Thorgeirsson UP: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 57: 3924-3928, 1997.
109. Karaiossifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S: Tumor angiogenesis in node- negative breast cancer: relationship with relapse free survival. Anticancer Res 16: 4001-4002, 1996.
110. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H, Tominaga T: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89: 139-147, 1997.
111. Engels K, Fox SB, Harris AL: Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. EXS 79: 113-156, 1997.
112. Simpson JF, Ahn C, Battifora H, Esteban JM: Endothelial area as a prognostic indicator for invasive breast carcinoma. Cancer 77: 2077-2085, 1996.
113. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL: Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 181: 207-212, 1997.
114. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832-10836, 1992.
115. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
116. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
117. Fidler IJ, Ellis LM: The implications of angiogenesis for the biology and therapy of cancermetastasis. Cell 79: 185-188, 1994.
118. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13: 765-782, 1995.
119. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996.
120. Folkman J: New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A: 2534-2539, 1996.
121. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57: 1829-1834, 1997.
122. D'Amato RJ, Loughman MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
123. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994.
124. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL: AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 34: 869-875, 1994.
125. Bosse DC, Parker JT, Vogler WR, Ades EW: Selective inhibition of adhesion molecule expression by edelfosine (ET-18-OCH3) on human umbilical vein or microvascular endothelium. Pathobiology 63: 109-114, 1995.
126. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 87: 581-586, 1995.
127. Konno H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S: Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77: 1736-1740, 1996.
128. Maier JA, Delia D, Thorpe PE, Gasparini G: In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1470 (TNP-410) and the anti-endoglin antibody TEC-11. Anticancer Drugs 8: 238-244, 1997.
129. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS: Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57: 5277-5280, 1997.
130. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
131. Klauber N, Parangi S, Flynn E, Hamel, E, D'Amato RJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86, 1997.
132. Sim BKL, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57: 1329-1334, 1997.
133. Lindner DJ, Borden EC: Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis. Int J Cancer 71: 456-461, 1997.
134. Meir EG van, Polverini PI, Chazin VR, Su Huang HJ, Tribolet N de, Cavenee WK: Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nature Genet 8: 171-176, 1994.
135. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.
136. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263-277, 1995.
137. Plate KH: Gene therapy of malignant glioma via inhibition of tumor angiogenesis. Cancer Metast Rev 15: 237-240, 1996.